The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

M.G. Dal Bello, R.A. Filiberti, A. Alama, A.M. Orengo, M. Mussap, S. Coco, I. Vanni, S. Boccardo, E. Rijavec, C. Genova, F. Biello, G. Barletta, G. Rossi, M. Tagliamento, C. Maggioni, F. Grossi

Research output: Contribution to journalArticle

Original languageEnglish
Article number74
JournalJournal of Translational Medicine
Volume17
Issue number1
DOIs
Publication statusPublished - 2019

Keywords

  • CEA
  • CYFRA21-1
  • Immunotherapy
  • NSCLC
  • Survival
  • Tumor response
  • carcinoembryonic antigen
  • cytokeratin 19 fragment
  • neuron specific enolase
  • nivolumab
  • adult
  • aged
  • Article
  • blood sampling
  • cancer immunotherapy
  • cancer patient
  • chemoluminescence
  • clinical evaluation
  • computer assisted tomography
  • controlled study
  • disease control
  • drug efficacy
  • drug withdrawal
  • female
  • human
  • human cell
  • immunoradiometric assay
  • major clinical study
  • male
  • middle aged
  • multiple cycle treatment
  • non small cell lung cancer
  • pathophysiology
  • patient monitoring
  • protein blood level
  • protein function
  • survival rate
  • treatment response
  • very elderly

Cite this

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. / Dal Bello, M.G.; Filiberti, R.A.; Alama, A.; Orengo, A.M.; Mussap, M.; Coco, S.; Vanni, I.; Boccardo, S.; Rijavec, E.; Genova, C.; Biello, F.; Barletta, G.; Rossi, G.; Tagliamento, M.; Maggioni, C.; Grossi, F.

In: Journal of Translational Medicine, Vol. 17, No. 1, 74, 2019.

Research output: Contribution to journalArticle

Dal Bello, M.G. ; Filiberti, R.A. ; Alama, A. ; Orengo, A.M. ; Mussap, M. ; Coco, S. ; Vanni, I. ; Boccardo, S. ; Rijavec, E. ; Genova, C. ; Biello, F. ; Barletta, G. ; Rossi, G. ; Tagliamento, M. ; Maggioni, C. ; Grossi, F. / The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. In: Journal of Translational Medicine. 2019 ; Vol. 17, No. 1.
@article{edebbb9d9ee04c75bdbb9ef9b42a044f,
title = "The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients",
keywords = "CEA, CYFRA21-1, Immunotherapy, NSCLC, Survival, Tumor response, carcinoembryonic antigen, cytokeratin 19 fragment, neuron specific enolase, nivolumab, adult, aged, Article, blood sampling, cancer immunotherapy, cancer patient, chemoluminescence, clinical evaluation, computer assisted tomography, controlled study, disease control, drug efficacy, drug withdrawal, female, human, human cell, immunoradiometric assay, major clinical study, male, middle aged, multiple cycle treatment, non small cell lung cancer, pathophysiology, patient monitoring, protein blood level, protein function, survival rate, treatment response, very elderly",
author = "{Dal Bello}, M.G. and R.A. Filiberti and A. Alama and A.M. Orengo and M. Mussap and S. Coco and I. Vanni and S. Boccardo and E. Rijavec and C. Genova and F. Biello and G. Barletta and G. Rossi and M. Tagliamento and C. Maggioni and F. Grossi",
note = "Export Date: 31 July 2019 Correspondence Address: Dal Bello, M.G.; Lung Cancer Unit, IRCCS-Ospedale Policlinico San MartinoItaly; email: mariagiovanna.dalbello@hsanmartino.it",
year = "2019",
doi = "10.1186/s12967-019-1828-0",
language = "English",
volume = "17",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

AU - Dal Bello, M.G.

AU - Filiberti, R.A.

AU - Alama, A.

AU - Orengo, A.M.

AU - Mussap, M.

AU - Coco, S.

AU - Vanni, I.

AU - Boccardo, S.

AU - Rijavec, E.

AU - Genova, C.

AU - Biello, F.

AU - Barletta, G.

AU - Rossi, G.

AU - Tagliamento, M.

AU - Maggioni, C.

AU - Grossi, F.

N1 - Export Date: 31 July 2019 Correspondence Address: Dal Bello, M.G.; Lung Cancer Unit, IRCCS-Ospedale Policlinico San MartinoItaly; email: mariagiovanna.dalbello@hsanmartino.it

PY - 2019

Y1 - 2019

KW - CEA

KW - CYFRA21-1

KW - Immunotherapy

KW - NSCLC

KW - Survival

KW - Tumor response

KW - carcinoembryonic antigen

KW - cytokeratin 19 fragment

KW - neuron specific enolase

KW - nivolumab

KW - adult

KW - aged

KW - Article

KW - blood sampling

KW - cancer immunotherapy

KW - cancer patient

KW - chemoluminescence

KW - clinical evaluation

KW - computer assisted tomography

KW - controlled study

KW - disease control

KW - drug efficacy

KW - drug withdrawal

KW - female

KW - human

KW - human cell

KW - immunoradiometric assay

KW - major clinical study

KW - male

KW - middle aged

KW - multiple cycle treatment

KW - non small cell lung cancer

KW - pathophysiology

KW - patient monitoring

KW - protein blood level

KW - protein function

KW - survival rate

KW - treatment response

KW - very elderly

U2 - 10.1186/s12967-019-1828-0

DO - 10.1186/s12967-019-1828-0

M3 - Article

VL - 17

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 74

ER -